Arena Pharmaceutical (ARNA) 1.78 $ARNA Arena (A
Post# of 273254
Posted On: 09/22/2016 3:06:17 AM
Arena Pharmaceutical (ARNA) 1.78 $ARNA
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34), ARNA: 1.78 (+0.07)
Arena Pharmaceutics Announces Formation of Beacon Discovery
PR Newswire - Thu Sep 01, 3:30PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"
, an independent, privately-held drug discovery incubator.
ARNA: 1.78 (+0.07)
Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:29AM CDT
Actelion (ALIOF) announced that Uptravi was granted approval by Swissmedic for treatment of patients with pulmonary arterial hypertension (PAH).
ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
PR Newswire - Mon Aug 15, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today. Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.
ARNA: 1.78 (+0.07)
Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 54.50 (-1.18), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon Aug 08, 3:01PM CDT
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the second quarter ended June 30, 2016, and provided a corporate update.
ARNA: 1.78 (+0.07)
Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.78 (+0.07), REGN: 406.52 (+0.28), NKTR: 19.15 (+0.18)
Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
ARNA: 1.78 (+0.07)
Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 3.18 (-0.01), ARNA: 1.78 (+0.07), EXEL: 14.74 (+0.58)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 91.82 (+0.13), XON: 28.11 (+0.23), ARNA: 1.78 (+0.07), REGN: 406.52 (+0.28)
Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
PR Newswire - Mon Jun 13, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in autoimmune diseases. Arena is currently studying etrasimod in a Phase 2 clinical trial for ulcerative colitis.
ARNA: 1.78 (+0.07)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.62 (+0.06), RTRX: 23.75 (+0.33), VVUS: 1.09 (+0.03), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.78 (+0.07)
Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 54.50 (-1.18), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.78 (+0.07)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (+0.04), INO: 9.80 (+0.43), VVUS: 1.09 (+0.03), TEVA: 50.48 (+0.12), ARNA: 1.78 (+0.07), PBYI: 67.97 (+2.81)
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34), ARNA: 1.78 (+0.07)
Arena Pharmaceutics Announces Formation of Beacon Discovery
PR Newswire - Thu Sep 01, 3:30PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"
, an independent, privately-held drug discovery incubator. ARNA: 1.78 (+0.07)
Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:29AM CDT
Actelion (ALIOF) announced that Uptravi was granted approval by Swissmedic for treatment of patients with pulmonary arterial hypertension (PAH).
ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
PR Newswire - Mon Aug 15, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today. Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.
ARNA: 1.78 (+0.07)
Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 54.50 (-1.18), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon Aug 08, 3:01PM CDT
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the second quarter ended June 30, 2016, and provided a corporate update.
ARNA: 1.78 (+0.07)
Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.78 (+0.07), REGN: 406.52 (+0.28), NKTR: 19.15 (+0.18)
Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
ARNA: 1.78 (+0.07)
Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 3.18 (-0.01), ARNA: 1.78 (+0.07), EXEL: 14.74 (+0.58)
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 91.82 (+0.13), XON: 28.11 (+0.23), ARNA: 1.78 (+0.07), REGN: 406.52 (+0.28)
Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
PR Newswire - Mon Jun 13, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in autoimmune diseases. Arena is currently studying etrasimod in a Phase 2 clinical trial for ulcerative colitis.
ARNA: 1.78 (+0.07)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.62 (+0.06), RTRX: 23.75 (+0.33), VVUS: 1.09 (+0.03), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.78 (+0.07)
Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 54.50 (-1.18), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ARNA: 1.78 (+0.07)
Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.78 (+0.07)
Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.78 (+0.07)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (+0.04), INO: 9.80 (+0.43), VVUS: 1.09 (+0.03), TEVA: 50.48 (+0.12), ARNA: 1.78 (+0.07), PBYI: 67.97 (+2.81)
(0)
(0)Scroll down for more posts ▼